web analytics
10.1 C
Friday, October 7, 2022

A Look at the New Stellar Biotechnologies Inc (OTCMKTS:SBOTD)

Stellar Biotechnologies Inc (OTCMKTS:SBOTD) has been one volatile stock since affecting the 1 for 10 reverse stock split on September 2. The stock has a history of big moves running from $0.60 to highs of $2.36 earlier this year.

SBOTD has been around for many years and was originally listed on the notorious Vancouver Stock Exchange. The Company is dually listed on the OTCBB and Canada’s TSX Venture Exchange where it trades under the symbol KLH. The recent surge in massive volume and upside comes on the heels of a significant promotion by Stansberry, Agora, Oxford and several others.

Stellar Biotechnologies Inc (OTCMKTS:SBOTD) is the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, infectious diseases, and immune disorders) as well as a finished product for measuring immune status.

The Company is unique in its proprietary methods, facilities, and KLH technology. We are committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies.

According to a recent email from Oil & Energy Investor ¨SBOTD has a monopoly over a breakthrough called living metal. Based on the 124 advanced clinical trials currently underway, it’s now believed that this discovery could be at the center of a series of miraculous treatments for Alzheimer’s, cancer, arthritis, and much more.¨

To Find out the inside Scoop on SBOTD Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

Back in July SBOTD reported Third Quarter 2014 Financial Results; Cash and cash equivalents as of May 31, 2014 were $14.8 million, compared to $ 7.9 million at year-end August 31, 2013. Revenues were $102,581 in the third quarter and $252,848 for the nine months ended May 31, 2014 compared to $73,214 and $250,422 in the comparable periods in 2013.

On September 5 SBOTD announced Stellar Biotechnologies Analyst Report; Early Mover in Fast Growing Immunotherapy Market by BrokerBank Securities, Inc.

SBOTD KLH protein is so unique because it can be sourced from the blood of only one rare sea animal, the California Keyhole Limpet which SBOTF farms in its own facility. The Keyhole Limpet can only be found off the coast of central California to Northern Baja. Stellar’s headquarters and aquaculture facility are situated in the center of those two locations. This is certainly an advantage that creates entry barriers but also creates big systemic vulnerability issues as well. How long it takes at maturity to produce the material and the ultimate quality level are still to be learned. This can be a decided advantage for aggressive traders and speculators but must be carefully considered as a risk for longer term investors.

On September 17 SBOTD announced its partner Neovacs recently presented promising extended follow-up data from the Phase I/IIa clinical trial of IFNa-Kinoid, which is being evaluated for the treatment of Systemic Erythematosus Lupus.

Stellar KLH(TM) is a primary component of Neovacs’ proprietary immunotherapy Kinoid technology and is the carrier molecule in Neovacs’ IFNa-Kinoid. Stellar and Neovacs recently entered into an expanded supply agreement to meet Neovacs’ clinical and commercial requirements for KLH.

Neovacs presented the promising extended follow-up data during Lupus 2015, the 11th International Congress on SLE, held September 2-6, 2015 in Vienna, Austria. The new data was collected as part of the Phase I/IIa extended follow-up study of six IFNa-Kinoid-treated patients.

We have a Monster Pick Coming. Subscribe Right Now!

SBOTD has $13.4 million in the treasury and is fully funded going forward. The Company is the leader in sustainable manufacture of Keyhole Limpet Hemocyanin, an important immune-stimulating protein used in wide-ranging immunotherapy markets. We will be updating on SBOTD when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with SBOTD.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in SBOTD either long or short and we have not been compensated for this article.

More articles



Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.